It dices, it splices!

摘要

The usual introduction for an MDS article includes a description of MDS as a group of heterogeneous clonal marrow disorders, characterized by cytopenias, dysplasia, and a variable propensity for progression to AML. While this statement remains true today, refinements to the MDS IPSS and the World Health Organization (WHO) classification criteria are expected as molecularly defined MDS subtypes emerge to replace the current "heterogeneous" characterization. Progress toward this goal includes the large-scale effort reported by Bejar et al demonstrating that point mutations in TP53, EZH2, ETV6, RUNX1, and ASXLl were significantly associated with poor survival in MDS independent of IPSS risk category.